1. Academic Validation
  2. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes

Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes

  • Nanomedicine. 2021 Oct;37:102439. doi: 10.1016/j.nano.2021.102439.
Anthony Moschetti 1 Ruben K Dagda 2 Robert O Ryan 3
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Biology, University of Nevada, Reno, NV.
  • 2 Department of Pharmacology, University of Nevada, Reno, NV.
  • 3 Department of Pharmacology, University of Nevada, Reno, NV. Electronic address: robertryan@unr.edu.
Abstract

Depletion of coenzyme Q (CoQ) is associated with disease, ranging from myopathy to heart failure. To induce a CoQ deficit, C2C12 myotubes were incubated with high dose simvastatin. This resulted in a concentration-dependent inhibition of cell viability. Simvastatin-induced effects were prevented by co-incubation with mevalonic acid. When myotubes were incubated with 60 μM simvastatin, mitochondrial CoQ content decreased while co-incubation with CoQ nanodisks (ND) increased mitochondrial CoQ levels and improved cell viability. Incubation of myotubes with simvastatin also led to a reduction in oxygen consumption rate (OCR). When myotubes were co-incubated with simvastatin and CoQ ND, the decline in OCR was ameliorated. The data indicate that CoQ ND represent a water soluble vehicle capable of delivering CoQ to cultured myotubes. Thus, these biocompatible nanoparticles have the potential to bypass poor CoQ oral bioavailability as a treatment option for individuals with severe CoQ deficiency syndromes and/or aging-related CoQ depletion.

Keywords

C2C12 myotubes; Coenzyme Q; Mitochondria; Nanodisk; Simvastatin.

Figures